stonks4u
Sign up free
BOLT logo

BOLT Bolt Biotherapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$3.35
+0.14 (+4.36%)

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2)…

Market Cap: $6.44Mwww.boltbio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 11Aug 11

Quote

Day Range
$3.20 – $3.36
52-Week Range
$3.13 – $7.20
Volume
$15.8K
Market Cap
$6.44M
50-Day Avg
$4.09
200-Day Avg
$4.84
Prev Close
$3.21
Open
$3.23

Valuation & Ratios

P/E Ratio
-0.31
EPS
$-17.85
P/B Ratio
0.39
P/S Ratio
1.33
Debt/Equity
0.87
Current Ratio
3.59
Dividend Yield
+0.0%
Gross Margin
+80.6%

Returns & Efficiency

Return on Equity
-125.9%
Return on Assets
-58.8%
FCF Yield
-390.3%
EV/EBITDA
-0.67

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$7.70M$-33.38M$-17.85
2024$7.69M$-63.12M$-1.65
2023$7.88M$-69.20M$-1.83
2022$5.73M$-88.10M$-2.30
2021$1.26M$-98.59M$-2.79

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-2.40 per share

5of 7 quarters beat consensus

Typical surprise +10.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-4.57 vs $-3.39miss
  • Tue, May 12$-4.31 vs $-2.85miss
  • Thu, Mar 12$-3.84 vs $-4.30beat
  • Wed, Nov 12$-3.72 vs $-5.07beat
  • Thu, Aug 14$-4.46 vs $-6.40beat
  • Mon, May 12$-5.80 vs $-6.80beat

Estimates and results for BOLT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

BOLThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newszacks.com·3d ago·Negative

    Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.

    View source ↗